Study guide

4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers

Key Takeaways Explain This Topic AI

MAGIC overall acute GVHD grade is derived from current skin, liver, upper-GI, and lower-GI staging; grade the worst current findings and continue a differential for infection, medication injury and other mimics.

The overall grade comes from the combination of current organ stages rather than from any single organ in isolation, so a moderate stage in two organs can outrank a higher stage in one.

The MAGIC Ann Arbor score uses plasma biomarkers to stratify risk and predict steroid responsiveness, complementing rather than replacing clinical organ staging.

Because grading is based on current findings, the grade is re-derived as organ stages change, making serial documentation of skin, liver, and gastrointestinal status a nursing responsibility rather than a one-time assessment.

Last updated: September 2026

MAGIC Grading, Acute GVHD Prophylaxis & Systemic Therapy

Core Clinical Principle: Acute Graft-versus-Host Disease management requires a two-pronged paradigm: proactive pharmacological prophylaxis to prevent alloreactive T-cell expansion, and aggressive, standardized clinical grading to guide systemic intervention when breakthrough GVHD occurs. The Mount Sinai Acute GVHD International Consortium (MAGIC) criteria represent the global standard for overall clinical grading. When systemic therapy is mandated, high-dose corticosteroids remain first-line, while prompt recognition of steroid refractoriness allows timely escalation to targeted second-line agents like the JAK1/2 inhibitor ruxolitinib.

1. Overall Clinical Severity Grading: The MAGIC Criteria

Individual target organ stages (Skin 0–4, Liver 0–4, Gastrointestinal 0–4) are synthesized into an overall clinical severity grade ranging from Grade 0 (Absent) to Grade IV (Extremely Severe / Life-Threatening) . Overall grade dictates systemic therapy decisions and strongly correlates with non-relapse mortality (NRM). +---------------------------------------------------------------------------------------------------+

  • | MAGIC OVERALL CLINICAL SEVERITY MATRIX |
  • | |
  • | GRADE 0: No Stage 1-4 involvement in any target organ |
  • | |
  • | GRADE I: Skin Stage 1-2 ONLY; Liver Stage 0; GI Stage 0 (Mild aGVHD) |
  • | |
  • | GRADE II: Skin Stage 3 AND/OR Liver Stage 1 AND/OR GI Stage 1 (or Upper GI Positive) |
  • | |
  • | GRADE III: Liver Stage 2-3 AND/OR GI Stage 2-3 (with Skin Stage 0-3) (Severe aGVHD) |
  • | |
  • | GRADE IV: Skin Stage 4 OR Liver Stage 4 OR GI Stage 4 (Extremely severe aGVHD) |
  • +---------------------------------------------------------------------------------------------------+
  • Detailed MAGIC Overall Grading Matrix

Overall Clinical Grade Cutaneous Stage Hepatic Stage Lower GI Stage Upper GI Symptoms Clinical Severity & Risk

Grade 0 Stage 0 (None) Stage 0 (None) Stage 0 (None) Negative No acute GVHD. Baseline observation.

Grade I Stage 1–2 (<50% BSA) Stage 0 (<2.0 mg/dL) Stage 0 (<500 mL/d) Negative Mild aGVHD. Managed with topical steroids; systemic therapy typically withheld.

Grade II Stage 3 (>50% BSA) and/or Stage 1 (2.0–3.0 mg/dL) and/or Stage 1 (500–999 mL/d) or Positive Moderate aGVHD. Assess for systemic therapy using organ pattern and protocol.

Grade III Stage 0–3 Stage 2–3 (3.1–15.0 mg/dL) and/or Stage 2–3 (1,000 mL/day or more without stage-4 symptoms) Any Severe aGVHD. High-risk disease requiring prompt protocol-directed systemic treatment.

Grade IV Stage 4 (bullae/desquamation >5% BSA) or Stage 4 (>15.0 mg/dL) or Stage 4 (severe abdominal pain with/without ileus or grossly bloody stool) Any Very severe aGVHD. High non-relapse risk; prompt second-line readiness.

Plasma Biomarkers in Acute GVHD (The MAGIC Ann Arbor Score)

In modern transplant centers, clinical grading is augmented by validated circulating plasma biomarkers measured at day 7, day 14, or at symptom onset:

ST2 (Suppression of Tumorigenicity 2): An IL-33 receptor family member released by damaged vascular endothelium and intestinal subepithelial myofibroblasts. Reflects mucosal and vascular tissue destruction.

REG3alpha (Regenerating Islet-Derived Protein 3-alpha): An antimicrobial peptide secreted by Paneth cells residing in intestinal crypts. Loss of Paneth cells leads to massive systemic release of REG3alpha into peripheral blood, serving as a specific biomarker for microscopic gastrointestinal crypt destruction.

MAGIC Ann Arbor Biomarker Scoring: Combines ST2 and REG3alpha concentrations to classify patients into Ann Arbor 1 (Low Risk) , Ann Arbor 2 (Intermediate Risk) , and Ann Arbor 3 (High Risk) . High-risk Ann Arbor 3 status predicts non-responsiveness to corticosteroids and high 6-month non-relapse mortality regardless of initial clinical grade.

Loading diagram... Acute GVHD Assessment and Escalation

2. The Organ Stage Cut Points the Grade Depends On

An overall grade cannot be assigned without the current stage in each organ, and the specific MAGIC thresholds are frequently tested because they differ from older Glucksberg-era criteria.

Organ Stage 1 Stage 2 Stage 3 Stage 4

Skin (active erythema) Rash under 25% BSA Rash 25 to 50% BSA Rash over 50% BSA Generalized erythema plus bullae or desquamation over 5% BSA

  • Liver (total bilirubin) 2 to 3 mg/dL 3.1 to 6 mg/dL 6.1 to 15 mg/dL Over 15 mg/dL
  • Upper GI Persistent nausea, vomiting, or anorexia Not defined Not defined Not defined

Lower GI (adult stool output) 500 to 999 mL/day 1,000 to 1,500 mL/day Over 1,500 mL/day Severe abdominal pain with or without ileus, or grossly bloody stool

Two structural features of this table drive most grading errors. Upper GI is binary : it is either stage 0 or stage 1, and there is no stage 2, 3, or 4 for upper gastrointestinal involvement. Lower GI stage 4 is defined by character, not volume : severe abdominal pain with or without ileus, or grossly bloody stool, is stage 4 no matter how many milliliters were measured. Pediatric lower-GI staging uses mL/kg/day rather than absolute volume, so an adult threshold applied to a child badly understages the disease.

3. Worked Grading Examples and the Common Traps

Case A. Rash over 30% body surface area, bilirubin 1.4 mg/dL, no diarrhea, intermittent nausea. Skin stage 2, liver stage 0, lower GI stage 0, upper GI stage 0. Skin stage 1 to 2 alone with no other organ involvement is overall Grade I .

Case B. Rash 10% body surface area, bilirubin 4.8 mg/dL, stool output 600 mL/day. Skin stage 1, liver stage 2, lower GI stage 1. Liver stage 2 places this at overall Grade III even though no single organ looks dramatic and the skin is barely involved.

Case C. No rash, bilirubin 1.0 mg/dL, stool output 900 mL/day with grossly bloody stool. Skin stage 0, liver stage 0, lower GI stage 4 by character. This is overall Grade IV on the strength of one organ, despite a volume that would otherwise be stage 1.

The traps these cases expose are worth naming explicitly. The overall grade is not the highest single organ stage, and it is not an average. A patient can be Grade III or IV with a completely normal skin examination. The grade is re-derived from current findings at each assessment rather than carried forward as the worst value ever recorded, so documented improvement genuinely lowers the grade. And because the grade drives therapy decisions, a nurse who measures and records stool volume, tracks bilirubin, and estimates rash body surface area accurately is supplying the primary data on which escalation depends.